Potentiation of metalloenediyne cytotoxicity by hyperthermia. 2011

Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

OBJECTIVE Enediynes are potent inducers of DNA damage, but their clinical usefulness has been limited. Here we report the thermal enhancement of cytotoxicity of two novel metalloenediyne compounds at concentrations that are either not or minimally cytotoxic at 37°C, and present evidence regarding possible mechanisms for enhanced cytotoxicity. METHODS HeLa cells were exposed to (Z)-N,N'-bis[1-pyridyl-2-yl-meth-(E)-ylidene]octa-4-ene-2,6-diyne-1,8-diamine (PyED) (which becomes metallated in culture medium) or ((Z)-N,N'-bis[quinolin-2-yl-meth-(E)-ylidene]octa-4-ene-2,6-diyne-1,8-diamine)zinc(II) chloride (QuinED · ZnCl(2)) at 37°C or 42.5°C for 1 h, and clonogenic survival was compared after treatment at each temperature. Analyses of cell cycle progression and mode of death were performed after treatments. RESULTS Treatment with PyED or QuinED · ZnCl(2) resulted in a significant decrease in cell survival when cells were treated with drug at 42.5°C compared to 37°C. Enhanced cytotoxicity was attributed to increased apoptosis. However, perturbation of the cell cycle may also play a role. Cells which were only heated or exposed to PyED at 37°C experienced significant G(2)/M blocks that were eliminated when PyED and heat were administered simultaneously, suggesting that combined treatments override cell cycle arrests normally observed with each agent individually. Conversely, cells heated during treatment with QuinED · ZnCl(2) displayed an increased G(2)/M arrest compared to treatment at 37°C. CONCLUSIONS With improvements in site-specific heat delivery to tumours, systemic administration of non-toxic metalloenediynes coupled with localised hyperthermia may improve selective enediyne activation/targeting. Therefore PyED and QuinED · ZnCl(2), which show significantly enhanced cytotoxicity at elevated temperatures, may represent viable candidates for thermochemotherapy.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D009942 Organometallic Compounds A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed) Metallo-Organic Compound,Metallo-Organic Compounds,Metalloorganic Compound,Organometallic Compound,Metalloorganic Compounds,Compound, Metallo-Organic,Compound, Metalloorganic,Compound, Organometallic,Compounds, Metallo-Organic,Compounds, Metalloorganic,Compounds, Organometallic,Metallo Organic Compound,Metallo Organic Compounds
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
January 1988, Cancer chemotherapy and pharmacology,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
January 1989, Anticancer research,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
June 1981, Gan,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
September 1997, Anti-cancer drugs,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
July 1979, International journal of radiation oncology, biology, physics,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
August 2018, Radiation research,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
January 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
October 1976, The British journal of radiology,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
January 1990, Anticancer research,
Stefan M Routt, and Ju Zhu, and Jeffrey M Zaleski, and Joseph R Dynlacht
April 1996, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!